Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,946.93 -122.75 (-0.31%) Hang Seng
19,220.62 -415.60 (-2.12%) FTSE 100
8,416.45 -7.75 (-0.09%) Bitcoin USD
69,707.83 +1,458.62 (+2.14%) CMC Crypto 200
1,518.08 +29.54 (+1.98%)
AN2 Therapeutics, Inc. (ANTX)
| Previous close | 2.2300 |
| Open | 2.2400 |
| Bid | 2.1800 x 200 |
| Ask | 2.2300 x 400 |
| Day's range | 2.2001 - 2.2500 |
| 52-week range | 2.2000 - 22.2200 |
| Volume | |
| Avg. volume | 316,303 |
| Market cap | 65.773M |
| Beta (5Y monthly) | -0.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround
AN2 Therapeutics (ANTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Insider Monkey
13 Best Falling Stocks To Buy Right Now
In this piece, we will take a look at the 13 best falling stocks to buy now. If you want to skip our coverage of the latest stock market news, then you can take a look at the 5 Best Falling Stocks To Buy Right Now. The start of the year has seen some stocks […]
- Reuters
UPDATE 1-AN2 Therapeutics to pause lung disease study enrollment
AN2 Therapeutics said on Monday it will pause further enrollment in a mid-to-late-stage study testing its experimental drug to treat a type of bacterial lung infection, citing potentially lower-than-expected efficacy. The company was conducting a mid-stage study testing epetraborole, a once-daily oral drug to treat MAC lung disease, caused by bacterial infection. AN2 said the decision to pause enrollment will give time to further evaluate the study data and it expects to announce top-line results from the study in the summer.
